Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aurinia Pharmaceuticals Inc. (AUPH)

4.95   -0.15 (-2.94%) 12-05 13:27
Open: 5.13 Pre. Close: 5.1
High: 5.115 Low: 4.94
Volume: 626,140 Market Cap: 703(M)

Technical analysis

as of: 2022-12-05 1:17:42 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 8.06     One year: 9.81
Support: Support1: 4.48    Support2: 3.73
Resistance: Resistance1: 6.9    Resistance2: 8.39
Pivot: 4.91
Moving Average: MA(5): 5.04     MA(20): 4.99
MA(100): 7.3     MA(250): 11.3
MACD: MACD(12,26): -0.5     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 55.2     %D(3): 53.2
RSI: RSI(14): 38.2
52-week: High: 24.45  Low: 4.48
Average Vol(K): 3-Month: 2,501 (K)  10-Days: 1,705 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AUPH ] has closed below upper band by 43.6%. Bollinger Bands are 69.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.12 - 5.14 5.14 - 5.16
Low: 4.86 - 4.89 4.89 - 4.91
Close: 5.06 - 5.1 5.1 - 5.13

Company Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Headline News

Wed, 30 Nov 2022
Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Drops By 27.7% - MarketBeat

Tue, 22 Nov 2022
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Thu, 10 Nov 2022
Insider Buying: The Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Chief Business Officer Just Bought 50% More Shares - Simply Wall St

Sun, 06 Nov 2022
Aurinia: Commercial Stage Company With Major Headwinds (NASDAQ:AUPH) - Seeking Alpha

Fri, 04 Nov 2022
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26% - Simply Wall St

Sun, 30 Oct 2022
Insiders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reaped rewards after their US$556k investment jumped another US$272k - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 142 (M)
Shares Float 131 (M)
% Held by Insiders 6.4 (%)
% Held by Institutions 41.8 (%)
Shares Short 11,460 (K)
Shares Short P.Month 12,500 (K)

Stock Financials

EPS -1.27
EPS Est Next Qtl -0.11
EPS Est This Year -1.01
EPS Est Next Year -0.39
Book Value (p.s.) 2.98
Profit Margin (%) -89.5
Operating Margin (%) -90
Return on Assets (ttm) -17.2
Return on Equity (ttm) -32
Qtrly Rev. Growth 280.2
Gross Profit (p.s.) -0.05
Sales Per Share 0.9
EBITDA (p.s.) -0.8
Qtrly Earnings Growth 0
Operating Cash Flow -116 (M)
Levered Free Cash Flow -72 (M)

Stock Valuations

PE Ratio -3.93
PEG Ratio 0
Price to Book value 1.66
Price to Sales 5.46
Price to Cash Flow -6.09

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.